NEW YORK, Feb. 20, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on BSX, HOLX, RMD, and WMGI which can be accessed for free by signing up to www.wallstequities.com/registration. Pre-market, WallStEquities.com concentrates on the Medical Appliances and Equipment industry, which primarily offers equipment and devices that are designed for the diagnosis, monitoring, and treatment of patients in healthcare systems worldwide. Stocks under assessment this morning are: Boston Scientific Corp. (NYSE: BSX), Hologic Inc. (NASDAQ: HOLX), ResMed Inc. (NYSE: RMD), and Wright Medical Group N.V. (NASDAQ: WMGI). All you have to do is sign up today for this free limited time offer by clicking the link below.
Massachusetts headquartered Boston Scientific Corp.'s shares recorded a trading volume of 6.71 million shares last Friday. The stock finished the trading session 0.41% higher at $27.20. The Company's shares have gained 7.26% over the past year. The stock is trading above its 50-day moving average by 3.01%. Furthermore, shares of Boston Scientific, which develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide, have a Relative Strength Index (RSI) of 53.87.
On January 24th, 2018, Boston Scientific (BSX) announced that it has closed an investment and entered into an acquisition option agreement with Millipede, Inc., a privately-held company that has developed the IRIS Transcatheter Annuloplasty Ring System for the treatment of severe mitral regurgitation. Under the terms of the agreements, BSX has purchased a portion of the outstanding shares of Millipede, along with newly issued shares of the company for a total consideration of $90 million. Get the full research report on BSX for free by clicking below at: www.wallstequities.com/registration/?symbol=BSX
On Friday, Massachusetts headquartered Hologic Inc.'s stock ended the session 0.28% higher at $39.29. A total volume of 3.12 million shares was traded, which was above their three months average volume of 2.81 million shares. The Company's shares have gained 0.10% over the previous three months. The stock is trading 5.03% below its 200-day moving average. Moreover, shares of Hologic, which develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the US, Europe, Asia/Pacific, and internationally, have an RSI of 36.09.
On February 09th, 2018, research firm Stifel downgraded the Company's stock rating from 'Buy' to 'Hold' while revising its previous target price from $45 a share to $42 a share.
On February 12th, 2018, Hologic announced that it will present at the following upcoming investor conferences: (i) The Raymond James 39th Annual Institutional Investors Conference on March 05th, 2018, at 9:50 a.m. ET in Orlando, Florida; (ii) Cowen and Company's 38th Annual Healthcare Conference on March 12th, 2018, at 2:10 p.m. ET in Boston, Massachusetts; and (iii) The Barclays Global Healthcare Conference on March 15th, 2018, at 8:30 a.m. ET in Miami, Florida. The free technical report on HOLX can be accessed at: www.wallstequities.com/registration/?symbol=HOLX
California headquartered ResMed Inc.'s stock ended the day 0.40% lower at $93.81. A total volume of 810,948 shares was traded, which was above their three months average volume of 701,030 shares. The Company's shares have gained 5.65% in the last month, 11.35% over the previous three months, and 30.44% over the past year. The stock is trading 4.19% and 17.03% above its 50-day and 200-day moving averages, respectively. Additionally, shares of ResMed have an RSI of 52.08.
On January 22nd, 2018, ResMed announced the results for its quarter ended December 31st, 2017. Revenue for Q2 of fiscal 2018 was $601.3 million; gross margin was 58.2%; and income from operations was $146.0 million. Net income for the quarter was $9.5 million; GAAP diluted earnings per share were $0.07; and cash flow from operations was $132.6 million.
On January 23rd, 2018, research firm Northland Capital upgraded the Company's stock rating from 'Underperform' to 'Market Perform'. Sign up for free on Wall St. Equities and claim the latest report on RMD at: www.wallstequities.com/registration/?symbol=RMD
Wright Medical Group
Shares in Netherlands headquartered Wright Medical Group N.V. recorded a trading volume of 983,145 shares. The stock ended Friday's session 1.76% lower at $20.06. The Company's shares are trading below their 50-day moving average by 11.55%. Furthermore, shares of the Company, which designs, manufactures, markets, and sells extremities and biologics products in the US, EMEA region, and internationally, have an RSI of 33.07.
On February 06th, 2018, Wright Medical announced that operating results for its Q4 ended December 31st, 2017, will be released on February 27th, 2018, at 3:00 p.m. CT. The Company will host a conference call at 3:30 p.m. CT that same day to discuss these results. A simultaneous webcast of the call will be available on the Company's corporate website. See the free research coverage on WMGI at: www.wallstequities.com/registration/?symbol=WMGI
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities